Home » Stocks » ENZ

Enzo Biochem, Inc. (ENZ)

Stock Price: $2.18 USD 0.01 (0.46%)
Updated December 3, 4:00 PM EST - Market closed

ENZ Stock Price Chart

Key Info

Market Cap 104.41M
Revenue (ttm) 76.02M
Net Income (ttm) -28.52M
Shares Out 47.70M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $2.18
Previous Close $2.17
Change ($) 0.01
Change (%) 0.46%
Day's Open 2.14
Day's Range 2.12 - 2.25
Day's Volume 210,547
52-Week Range 1.82 - 3.87

ENZ Stock News

GlobeNewsWire - 1 week ago

NEW YORK, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD,...

GlobeNewsWire - 2 weeks ago

NEW YORK, NY, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, M...

GlobeNewsWire - 1 month ago

Direct-to-Consumer service will initially offer access to COVID-19 molecular and antibody testing and will expand to include other testing in the future

Seeking Alpha - 1 month ago

Enzo Biochem, Inc.'s (ENZ) on Q4 2020 Results - Earnings Call Transcript

GlobeNewsWire - 1 month ago

Conference call and live webcast scheduled for today, Tuesday, October 13, 2020 at 4:30 pm (ET)

GlobeNewsWire - 1 month ago

Conference Call and Webcast Scheduled for October 13, 2020, 4:30 pm ET

Seeking Alpha - 2 months ago

Enzo Biochem, Inc: Wildly Undervalued COVID-19 Test Play With Near-Term Catalysts

GlobeNewsWire - 4 months ago

New initiative introduces Enzo’s Independent Pharmacy Testing Program with full range of products and services to support rapid and accurate testing to more residents of New York State New ini...

Market Watch - 4 months ago

Shares of Enzo Biochem Inc. ENZ, +6.71% rallied 7.7% in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for ...

GlobeNewsWire - 4 months ago

Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIP...

GlobeNewsWire - 5 months ago

First Collaboration under Enzo’s School and Institution Testing (“SIT”) Program

GlobeNewsWire - 5 months ago

Continues to Explore Opportunities for Use of the Compound as a Potential Treatment for COVID-19

Seeking Alpha - 5 months ago

Enzo Biochem, Inc. (ENZ) Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020.

GlobeNewsWire - 6 months ago

Second Product Offering to Expand Disease Management within Enzo’s Comprehensive COVID-19 Program

GlobeNewsWire - 7 months ago

NEW YORK, NY, April 29, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.  (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624...

Benzinga - 7 months ago

Enzo Biochem, Inc. (NYSE: ENZ) shares were rallying Thursday following an update from the company on its comprehensive COVID-19 program.

Benzinga - 8 months ago

The COVID-19 outbreak has proved to be a catalyst for biotechs. Some issues that were wallowing in penny stock territory have posted stratospheric gains in the wake of efforts to develop diagn...

Other stocks mentioned: NNVC, OPK, SPEX
Seeking Alpha - 11 months ago

Enzo Biochem, Inc. (ENZ) Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Enzo Biochem, Inc. (ENZ) Management on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Enzo Biochem, Inc. (ENZ) Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Enzo Biochem, Inc. (ENZ) Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Enzo Biochem, Inc. (ENZ) President Barry Weiner on Q3 2019 Results - Earnings Call Transcript

About ENZ

Enzo Biochem, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and... [Read more...]

Industry
Diagnostics & Research
Founded
1976
CEO
Elazar Rabbani
Employees
408
Stock Exchange
NYSE
Ticker Symbol
ENZ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Enzo Biochem is 5.50, which is an increase of 152.29% from the latest price.

Price Target
$5.50
(152.29% upside)